Jacobson Pharma Corporation

Jacobson Pharma Corporation ROE

The Return on Equity (ROE) of Jacobson Pharma Corporation (2633.HK) as of Nov 5, 2026 is 13.02 %. In the previous year, Return on Equity (ROE) was 12.26 % — a change of 6.20% (higher).

ROE

13.02 %

YoY

6.20%

Last updated:

In 2026, Jacobson Pharma Corporation's return on equity (ROE) was 13.02 %, a 6.20% increase from the 12.26 % ROE in the previous year.

The Jacobson Pharma Corporation ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
9.47 HKD
Jan 1, 2020
8.50 HKD
Jan 1, 2021
7.27 HKD
Jan 1, 2022
7.13 HKD
Jan 1, 2023
9.17 HKD
Jan 1, 2024
11.25 HKD
Jan 1, 2025
12.26 HKD
Jan 1, 2026
13.02 HKD
The Jacobson Pharma Corporation ROE history
YEARROEYoY
13.02 %+6.20%
12.26 %+8.96%
11.25 %+22.69%
9.17 %+28.63%
7.13 %-1.89%
7.27 %-14.45%
8.50 %-10.23%
9.47 %-7.54%
10.24 %-0.13%
10.25 %-36.16%
16.06 %+50.84%
10.64 %-45.78%
19.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jacobson Pharma Corporation Stock analysis

What does Jacobson Pharma Corporation do? Jacobson Pharma Corp. Ltd. generates revenue through its Generic Drugs segment, which develops, manufactures, and distributes off-patent medicines for public and private sectors. The Branded Healthcare segment offers branded medicines, proprietary Chinese medicines, and health and wellness products. Both segments operate primarily in Hong Kong, serving healthcare providers and consumers seeking cost-effective pharmaceutical solutions. The company employs 1,789 full-time employees to support its operations across these segments. The Generic Drugs segment focuses on off-patent medicines for various therapeutic uses, targeting hospitals, clinics, and pharmacies in both public and private healthcare systems. The Branded Healthcare segment caters to consumers and healthcare providers through branded pharmaceuticals and wellness products, emphasizing proprietary Chinese medicines as a key offering. Revenue streams are derived from direct sales of these products within Hong Kong's healthcare market. Jacobson Pharma's business model relies on the dual revenue streams from generic and branded pharmaceuticals. The company's product portfolio includes off-patent medicines under the Generic Drugs segment and branded medicines under the Branded Healthcare segment, both contributing to its overall sales. The firm's operations are structured around these two segments, with all activities concentrated in Hong Kong. Jacobson Pharma Corporation is one of the most popular companies on Eulerpool.

ROE Details

Decoding Jacobson Pharma Corporation's Return on Equity (ROE)

Jacobson Pharma Corporation's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Jacobson Pharma Corporation's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Jacobson Pharma Corporation's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Jacobson Pharma Corporation’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Jacobson Pharma Corporation stock

Return on Equity (ROE) of Jacobson Pharma Corporation is 13.02 % in 2026.

Return on Equity (ROE) of Jacobson Pharma Corporation changed from 12.26 % to 13.02 %, representing a 6.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Jacobson Pharma Corporation since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Jacobson Pharma Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Jacobson Pharma Corporation

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Jacobson Pharma Corporation